FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201368637> ?p ?o ?g. }

• W3201368637 endingPage "1135" @default.
• W3201368637 startingPage "1123" @default.
• W3201368637 abstract "Continuous antipsychotic therapy is recommended as part of long-term maintenance treatment of schizophrenia, and gaps in antipsychotic treatment have been associated with increased risks of relapse and rehospitalization. Because the use of long-acting injectable (LAI) antipsychotics may reduce the likelihood of undetected medication gaps, initiating an LAI medication may affect resource utilization and costs. The LAI aripiprazole lauroxil (AL) was approved in the United States (US) in 2015 for the treatment of schizophrenia in adults. The objective of this retrospective observational cohort study was to examine treatment patterns, resource utilization, and costs following initiation of AL for the treatment of schizophrenia in adults. A retrospective analysis of Medicaid claims data identified a cohort of patients (N = 485) starting AL shortly after Food and Drug Administration approval in October 2015. Treatment patterns, resource utilization, and costs were compared 6 months before and after treatment initiation. Subgroup analyses were conducted based on the type of antipsychotic (LAI, oral, or none) received before initiation of AL. Over 6 months of follow-up, patients received an average of 4.6 injections out of a maximum of six (77%). After initiating AL, all-cause inpatient admissions decreased by 22.4%; other significant reductions were observed in mental health–related admissions and emergency room (ER) visits. All-cause inpatient costs decreased by an average of US$2836 per patient (p < 0.05) in the 6-month post-AL period, whereas outpatient pharmacy costs increased by US$4121 (p < 0.05), resulting in no significant difference in overall costs between the pre- and post-AL periods. The subgroup of patients who had been prescribed an oral antipsychotic before starting AL had significant reductions in proportion of patients with inpatient and ER visits and costs, but also reported a significant increase in pharmacy costs. AL was associated with a significant reduction in inpatient costs and an increase in outpatient pharmacy costs, resulting in no changes in total healthcare costs over 6 months. The adherence rate and reductions in inpatient use may indicate the potential for greater clinical stability among patients initiated on AL compared with their previous treatment." @default.
• W3201368637 created "2021-09-27" @default.
• W3201368637 creator A5006221714 @default.
• W3201368637 creator A5025726979 @default.
• W3201368637 creator A5036524519 @default.
• W3201368637 creator A5047418643 @default.
• W3201368637 creator A5072573097 @default.
• W3201368637 creator A5088123374 @default.
• W3201368637 creator A5088559086 @default.
• W3201368637 creator A5091319547 @default.
• W3201368637 date "2021-09-21" @default.
• W3201368637 modified "2023-10-06" @default.
• W3201368637 title "Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia" @default.
• W3201368637 cites W1969060266 @default.
• W3201368637 cites W1991696949 @default.
• W3201368637 cites W1997542765 @default.
• W3201368637 cites W2016968691 @default.
• W3201368637 cites W2053705303 @default.
• W3201368637 cites W2063800690 @default.
• W3201368637 cites W2088044851 @default.
• W3201368637 cites W2099477707 @default.
• W3201368637 cites W2114066392 @default.
• W3201368637 cites W2119971225 @default.
• W3201368637 cites W2121393149 @default.
• W3201368637 cites W2129168200 @default.
• W3201368637 cites W2138418531 @default.
• W3201368637 cites W2143855802 @default.
• W3201368637 cites W2165397843 @default.
• W3201368637 cites W2285263567 @default.
• W3201368637 cites W2314672184 @default.
• W3201368637 cites W2317070629 @default.
• W3201368637 cites W2520092610 @default.
• W3201368637 cites W2527103551 @default.
• W3201368637 cites W2594212608 @default.
• W3201368637 cites W2603711939 @default.
• W3201368637 cites W2604955719 @default.
• W3201368637 cites W2756227090 @default.
• W3201368637 cites W2801704870 @default.
• W3201368637 cites W2801804534 @default.
• W3201368637 cites W2888733935 @default.
• W3201368637 cites W2892796001 @default.
• W3201368637 cites W2904839581 @default.
• W3201368637 cites W2912654919 @default.
• W3201368637 cites W2991428633 @default.
• W3201368637 cites W2999488690 @default.
• W3201368637 cites W3017140616 @default.
• W3201368637 doi "https://doi.org/10.1007/s40263-021-00849-2" @default.
• W3201368637 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8478765" @default.
• W3201368637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34546558" @default.
• W3201368637 hasPublicationYear "2021" @default.
• W3201368637 type Work @default.
• W3201368637 sameAs 3201368637 @default.
• W3201368637 citedByCount "7" @default.
• W3201368637 countsByYear W32013686372021 @default.
• W3201368637 countsByYear W32013686372022 @default.
• W3201368637 countsByYear W32013686372023 @default.
• W3201368637 crossrefType "journal-article" @default.
• W3201368637 hasAuthorship W3201368637A5006221714 @default.
• W3201368637 hasAuthorship W3201368637A5025726979 @default.
• W3201368637 hasAuthorship W3201368637A5036524519 @default.
• W3201368637 hasAuthorship W3201368637A5047418643 @default.
• W3201368637 hasAuthorship W3201368637A5072573097 @default.
• W3201368637 hasAuthorship W3201368637A5088123374 @default.
• W3201368637 hasAuthorship W3201368637A5088559086 @default.
• W3201368637 hasAuthorship W3201368637A5091319547 @default.
• W3201368637 hasBestOaLocation W32013686371 @default.
• W3201368637 hasConcept C104863432 @default.
• W3201368637 hasConcept C118552586 @default.
• W3201368637 hasConcept C126322002 @default.
• W3201368637 hasConcept C160735492 @default.
• W3201368637 hasConcept C162324750 @default.
• W3201368637 hasConcept C167135981 @default.
• W3201368637 hasConcept C187212893 @default.
• W3201368637 hasConcept C194828623 @default.
• W3201368637 hasConcept C2776412080 @default.
• W3201368637 hasConcept C2776534028 @default.
• W3201368637 hasConcept C2780211496 @default.
• W3201368637 hasConcept C2780494398 @default.
• W3201368637 hasConcept C50522688 @default.
• W3201368637 hasConcept C512399662 @default.
• W3201368637 hasConcept C71924100 @default.
• W3201368637 hasConcept C72563966 @default.
• W3201368637 hasConceptScore W3201368637C104863432 @default.
• W3201368637 hasConceptScore W3201368637C118552586 @default.
• W3201368637 hasConceptScore W3201368637C126322002 @default.
• W3201368637 hasConceptScore W3201368637C160735492 @default.
• W3201368637 hasConceptScore W3201368637C162324750 @default.
• W3201368637 hasConceptScore W3201368637C167135981 @default.
• W3201368637 hasConceptScore W3201368637C187212893 @default.
• W3201368637 hasConceptScore W3201368637C194828623 @default.
• W3201368637 hasConceptScore W3201368637C2776412080 @default.
• W3201368637 hasConceptScore W3201368637C2776534028 @default.
• W3201368637 hasConceptScore W3201368637C2780211496 @default.
• W3201368637 hasConceptScore W3201368637C2780494398 @default.
• W3201368637 hasConceptScore W3201368637C50522688 @default.
• W3201368637 hasConceptScore W3201368637C512399662 @default.
• W3201368637 hasConceptScore W3201368637C71924100 @default.
• W3201368637 hasConceptScore W3201368637C72563966 @default.

• next